Saroglitazar for the treatment of dyslipidemia in diabetic patients

Bibliography

• Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard School of Public Health, Boston; 1996
   Google Scholar
• Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases, part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-53
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52
   PubMed Web of Science ®Google Scholar
• Wild SH, Byrne CD, Tzoulaki I, et al. Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: the Edinburgh Artery Study. Atherosclerosis 2009;203(2):604-9
   PubMed Web of Science ®Google Scholar
• Rodriguez-Colon SM, Mo J, Duan Y, et al. Metabolic syndrome clusters and the risk of incident stroke: the atherosclerosis risk in communities (ARIC) study. Stroke 2009;40(1):200-5
   PubMed Web of Science ®Google Scholar
• Joshi SR, Anjana RM, Deepa M, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR–INDIAB Study. PLoS One 2014;9(5):e96808
   PubMed Web of Science ®Google Scholar
• Parikh RM, Joshi SR, Menon PS, Shah NS. Diabetes & Metabolic Syndrome: Clinical Research&Reviews. Diabetes Metab Syndr Clin Res Rev 2010;4(1):10-12
   Google Scholar
• Murad MH, Hazem A, Coto-Yglesias F, et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord 2012;12:2
   PubMed Web of Science ®Google Scholar
• Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011;28:1343-51
   PubMed Web of Science ®Google Scholar
• Feher M, Greener M, Munro N. Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2013;6:11-15
   PubMedGoogle Scholar
• Harchaoui KEL, Visser ME, Kastelein JJP, et al. Triglycerides and cardiovascular risk. Curr Cardiol Rev 2009;5(3):216-22
   PubMedGoogle Scholar
• Jeppesen J, Ole Hein H, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9:258-70
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, Backer GD, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99(6A):3C-18C
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. Eur J Clin Invest 2013;43(5):522-31
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS,. Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity. Curr Pharm Des 2008;14(6):574-87
   PubMed Web of Science ®Google Scholar
• AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279-91
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Wu JH. Omega-3 fatty acids and CVD: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58:2047-67
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (amr101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial). Am J Cardiol 2011;108:682-90
   PubMed Web of Science ®Google Scholar
• The ORIGIN Trial Investigators. Bosch J, Gerstein HC, Dagenais GR, et al. n–3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18
   PubMed Web of Science ®Google Scholar
• Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771(8):1065-81
   PubMed Web of Science ®Google Scholar
• Escher P, Braissant O, Basu-Modak S, et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001;142(10):4195-202
   PubMed Web of Science ®Google Scholar
• Chang F, Jaber LA, Berlie HD, O’Connell MB. Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 2007;41(6):973-83
   PubMed Web of Science ®Google Scholar
• Feige JN, Gelman L, Michalik L, et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006;45(2):120-59
   PubMed Web of Science ®Google Scholar
• Balakumar P, Rose M, Ganti SS, et al. PPAR dual agonists: are they opening pandora’s box? Pharmacol Res 2007;56(2):91-8
   PubMed Web of Science ®Google Scholar
• Hsiao A, Worrall DS, Olefsky JM, Subramaniam S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 2004;20(17):3108-27
   PubMed Web of Science ®Google Scholar
• Pai V, Paneerselvam A, Mukhopadhyay S, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol 2014;8(1):132-41
   PubMedGoogle Scholar
• Jani RH, Pai V, Jha P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther 2014;16(2):63-71
   PubMed Web of Science ®Google Scholar
• Raval P, Jain M, Goswami A, et al. Revisiting glitazars: thiophene substituted oxazole containing a-ethoxy phenylpropanoic acid derivatives as highly potent PPARa/c dual agonists devoid of adverse effects in rodents. Bioorg Med Chem Lett 2011;21:3103-9
   PubMed Web of Science ®Google Scholar
• Lipaglyn product monograph, Saroglitazar, Zydus Discovery. Available from: http://lipaglyn.com/downloads/Lipaglyn_Product_Monograph.pdf [Accessed on 06 November 2014]
   Google Scholar
• Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007;125:451-72
   PubMed Web of Science ®Google Scholar
• Karimi I. Animal models as tools for translational research: focus on atherosclerosis, metabolic syndrome and type-II diabetes mellitus. http://dx.doi.org/10.5772/47769 [Accessed on 06 November 2014]
   Google Scholar
• Jain MR, Giri SR, Sundar R, et al. ZYH1, a Novel PPAR Agonist that shows lipid-lowering and insulin-sensitizing effects with good safety profile in preclinical models. Diabetes 2012;61(Suppl 1A):A269-70
   Google Scholar
• Jani RH, Kansagra K, Jain MR, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects. Clin Drug Investig 2013;33(11):809-16
   PubMed Web of Science ®Google Scholar
• Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006;35:491-510
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: united Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316(7134):823-8
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
   PubMed Web of Science ®Google Scholar
• Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29(6):1220-6
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96
   PubMed Web of Science ®Google Scholar
• Available from: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1322&EncHid=&userName=saroglitazar [Accessed on 14 July 2014]
   Google Scholar
• Available from: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1323&EncHid=&userName=saroglitazar [Accessed on 14 July 2014]
   Google Scholar
• Available from: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=6705&EncHid=&userName=saroglitazar [Accessed on 14 July 2014]
   Google Scholar
• Available from: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=9538&EncHid=&userName=saroglitazar [Accessed on 9 September 2014]
   Google Scholar
• Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001;249:225-35
   PubMed Web of Science ®Google Scholar
• Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008;371:1800-9
   PubMed Web of Science ®Google Scholar
• Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-36
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279-89
   PubMed Web of Science ®Google Scholar
• Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013;30(9):1026-32
   PubMed Web of Science ®Google Scholar
• Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone interim report of a longitudinal cohort study. Diabetes Care 2011;34(4):916-22
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: angel or demon? Curr Pharm Des 2013;19(27):4913-29
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71
   PubMed Web of Science ®Google Scholar
• Balas B, Belfort R, Harrison SA, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 2007;47:565-70
   PubMed Web of Science ®Google Scholar
• Ruano G, Bernene J, Windemuth A, et al. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin Chim Acta 2009;400:48-55
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1563-74
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849-61
   PubMed Web of Science ®Google Scholar
• Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009;32(3):493-8
   PubMed Web of Science ®Google Scholar
• Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363(7):692-4
   PubMed Web of Science ®Google Scholar
• Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;371:32-41
   PubMed Web of Science ®Google Scholar
• Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154(5):943-53
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabtes mellitus. N Engl J Med 2010;362:1563-74
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus the AleCardio randomized clinical trial. JAMA 2014;311(15):1515-25
   PubMed Web of Science ®Google Scholar